

CEEAO International WebAcademy Journal Club

Free Online Webinar 15 June, 2021.- 15.00-16.00 CET

Webinar for medical-, surgical-, radio oncologists, medical students, residensts

Official languages of the webinar are English and Russian with simultaneous interpretation.

Presenters:

Dr. Gábor RubovszkyHead of Dept of Chemotherapy,
National Institute of Oncology, Hungary

Dr. Borbála SzékelyDept of Chemotherapy,
National Institute of Oncology, Hungary

Paper presented: M A Franzoi, E Romano, M Piccart Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol2021 Mar;32(3):323-336.

Short summary of the presentation:

As hormonereceptor-positive tumors have a characteristic to recur even decades after the treatment of the primary tumor, the possibility of inducing immunological memory with ICIs is especially compelling in early disease. Moreover, for aggressive tumors like TNBC, for which there is a paucity of effective treatments for metastatic disease, improving the chances of cure with the addition of these agents seems a logical approach. Multiple clinical trials using immunotherapy in breast cancer (BC) are ongoing, these trials are being conducted in parallel in the metastatic and early setting. Most of the ongoing studies are recruiting, targeting PD-1 or PD-L1 in combination with other modalities, being conducted in TNBC and Luminal B BC, and the majority is treating patients in the neoadjuvant setting. The paper analyses different clinical trials based on BC subtype and on modalities used in combination with the immunotherapy (CDK 4/6 inhibitors, anti-HER2 agents, MEKand AKT inhibitors, PARP-inhibitors or radiotherapy), and also discusses the role of immune-related biomarkers.